3rd Aug 2009 07:00
03 August 2009
HENDERSON MORLEY PLC
(AIM: HML)
("Henderson Morley" "HM" or "the Company")
National Institute of Health Grant Application
The Board of Henderson Morley, the AIM quoted biotechnology company, is pleased to update the market on previous announcements regarding the Company's Collaborative Research Agreement with the Australian Centre for Vaccine Development ("ACVD"), and the submission of a grant application to the US government funded National Institute of Health ("NIH").
The grant application has now been submitted with the goal of securing non-dilutive funding to further develop the Cytomegalovirus ("CMV") Vaccine candidate (part of the PREPS and L-particles vaccine platform). The development of a vaccine for CMV is a priority for the NIH and has been identified as a pathogen that has a significant impact on public health.
Prof Rajiv Khanna, of the ACVD is leading the Australian research, and stated: "Henderson Morley's technology, and the vaccine design expertise of the Queensland Institute of Medical Research (QIMR), Australia, constitutes a unique and powerful approach to the development of a vaccine for CMV. The Poly-L particle approach, patented by Henderson Morley, is unparalleled in the United States.
The HM/QIMR approach circumvents the confounding factors that have prevented a functional vaccine in the past. The impact of a successful vaccine would be the prevention of thousands of CMV infections in newborn and immunocompromised patients, and could save millions of dollars in hospitalization costs for the treatment of this deadly and evasive pathogen''
Andrew Knight, Executive Chairman, commented:
''We are of course very pleased to be working on this project with the QIMR, which is the largest Medical Research Institute in Australia. The Institute is recognized for world-class research in various areas including immunology, infectious diseases cancer research, genetics and epidemiology.''
--END--
ENQUIRIES:
HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman
BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
(Public Relations)
Maxine Barnes Gemma O'Hara
BREWIN DOLPHIN INVESTMENT BANKING 0113 241 0126
(Nominated Adviser)
Neil Baldwin
RIVINGTON STREET CORPORATE FINANCE LTD 020 7562 3380
(Broker)
Monisha Varadan
Related Shares:
HML.L